Pharmacodynamics of Minocycline against in a Rat Pneumonia Model.

Minocycline is currently approved in the United States for the treatment of infections caused by susceptible isolates of spp. The objective of these studies was to determine the minocycline exposures associated with an antibacterial effect against in a rat pneumonia model. Rats received minocycline doses as 30-min intravenous infusions. In the rat pneumonia model, six clinical isolates of with MICs ranging from 0.03 to 4 mg/liter were studied. In this model, minocycline produced a bacteriostatic effect with a free 24-h area under the concentration-time curve (AUC)/MIC ratio of 10 to 16 and produced 1 log of bacterial killing with a free 24-h AUC/MIC of 13 to 24. These exposures can be achieved with the current FDA-approved dosage regimens of intravenous minocycline.